Cargando…

Differences in SARS-CoV-2 Clinical Manifestations and Disease Severity in Children and Adolescents by Infecting Variant

Since the COVID-19 pandemic began, different SARS-CoV-2 variants have been identified and associated with higher transmissibility than the ancestral nonvariant strain. During January 1, 2021–January 15, 2022, we assessed differences in clinical and viral parameters in a convenience sample of COVID-1...

Descripción completa

Detalles Bibliográficos
Autores principales: Quintero, Ana Maria, Eisner, Mariah, Sayegh, Rouba, Wright, Tori, Ramilo, Octavio, Leber, Amy L., Wang, Huanyu, Mejias, Asuncion
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Centers for Disease Control and Prevention 2022
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9622241/
https://www.ncbi.nlm.nih.gov/pubmed/36285986
http://dx.doi.org/10.3201/eid2811.220577
_version_ 1784821718071640064
author Quintero, Ana Maria
Eisner, Mariah
Sayegh, Rouba
Wright, Tori
Ramilo, Octavio
Leber, Amy L.
Wang, Huanyu
Mejias, Asuncion
author_facet Quintero, Ana Maria
Eisner, Mariah
Sayegh, Rouba
Wright, Tori
Ramilo, Octavio
Leber, Amy L.
Wang, Huanyu
Mejias, Asuncion
author_sort Quintero, Ana Maria
collection PubMed
description Since the COVID-19 pandemic began, different SARS-CoV-2 variants have been identified and associated with higher transmissibility than the ancestral nonvariant strain. During January 1, 2021–January 15, 2022, we assessed differences in clinical and viral parameters in a convenience sample of COVID-19 outpatients and inpatients 0–21 years of age in Columbus, Ohio, USA, according to the infecting variant, identified using a mutation-specific reverse transcription PCR assay. Of the 676 patients in the study, 17.75% were infected with nonvariant strains, 18.49% with the Alpha variant, 41.72% with Delta, and 16.42% with Omicron. Rates of SARS-COV-2/viral co-infections were 15.66%–29.41% and were comparable across infecting variants. Inpatients with acute Delta and Omicron infections had lower SARS-CoV-2 cycle threshold values and more frequent fever and respiratory symptoms than those with nonvariant strain infections. In addition, SARS-COV-2/viral co-infections and the presence of underlying conditions were independently associated with worse clinical outcomes, irrespective of the infecting variant.
format Online
Article
Text
id pubmed-9622241
institution National Center for Biotechnology Information
language English
publishDate 2022
publisher Centers for Disease Control and Prevention
record_format MEDLINE/PubMed
spelling pubmed-96222412022-11-05 Differences in SARS-CoV-2 Clinical Manifestations and Disease Severity in Children and Adolescents by Infecting Variant Quintero, Ana Maria Eisner, Mariah Sayegh, Rouba Wright, Tori Ramilo, Octavio Leber, Amy L. Wang, Huanyu Mejias, Asuncion Emerg Infect Dis Research Since the COVID-19 pandemic began, different SARS-CoV-2 variants have been identified and associated with higher transmissibility than the ancestral nonvariant strain. During January 1, 2021–January 15, 2022, we assessed differences in clinical and viral parameters in a convenience sample of COVID-19 outpatients and inpatients 0–21 years of age in Columbus, Ohio, USA, according to the infecting variant, identified using a mutation-specific reverse transcription PCR assay. Of the 676 patients in the study, 17.75% were infected with nonvariant strains, 18.49% with the Alpha variant, 41.72% with Delta, and 16.42% with Omicron. Rates of SARS-COV-2/viral co-infections were 15.66%–29.41% and were comparable across infecting variants. Inpatients with acute Delta and Omicron infections had lower SARS-CoV-2 cycle threshold values and more frequent fever and respiratory symptoms than those with nonvariant strain infections. In addition, SARS-COV-2/viral co-infections and the presence of underlying conditions were independently associated with worse clinical outcomes, irrespective of the infecting variant. Centers for Disease Control and Prevention 2022-11 /pmc/articles/PMC9622241/ /pubmed/36285986 http://dx.doi.org/10.3201/eid2811.220577 Text en https://creativecommons.org/licenses/by/4.0/Emerging Infectious Diseases is a publication of the U.S. Government. This publication is in the public domain and is therefore without copyright. All text from this work may be reprinted freely. Use of these materials should be properly cited.
spellingShingle Research
Quintero, Ana Maria
Eisner, Mariah
Sayegh, Rouba
Wright, Tori
Ramilo, Octavio
Leber, Amy L.
Wang, Huanyu
Mejias, Asuncion
Differences in SARS-CoV-2 Clinical Manifestations and Disease Severity in Children and Adolescents by Infecting Variant
title Differences in SARS-CoV-2 Clinical Manifestations and Disease Severity in Children and Adolescents by Infecting Variant
title_full Differences in SARS-CoV-2 Clinical Manifestations and Disease Severity in Children and Adolescents by Infecting Variant
title_fullStr Differences in SARS-CoV-2 Clinical Manifestations and Disease Severity in Children and Adolescents by Infecting Variant
title_full_unstemmed Differences in SARS-CoV-2 Clinical Manifestations and Disease Severity in Children and Adolescents by Infecting Variant
title_short Differences in SARS-CoV-2 Clinical Manifestations and Disease Severity in Children and Adolescents by Infecting Variant
title_sort differences in sars-cov-2 clinical manifestations and disease severity in children and adolescents by infecting variant
topic Research
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9622241/
https://www.ncbi.nlm.nih.gov/pubmed/36285986
http://dx.doi.org/10.3201/eid2811.220577
work_keys_str_mv AT quinteroanamaria differencesinsarscov2clinicalmanifestationsanddiseaseseverityinchildrenandadolescentsbyinfectingvariant
AT eisnermariah differencesinsarscov2clinicalmanifestationsanddiseaseseverityinchildrenandadolescentsbyinfectingvariant
AT sayeghrouba differencesinsarscov2clinicalmanifestationsanddiseaseseverityinchildrenandadolescentsbyinfectingvariant
AT wrighttori differencesinsarscov2clinicalmanifestationsanddiseaseseverityinchildrenandadolescentsbyinfectingvariant
AT ramilooctavio differencesinsarscov2clinicalmanifestationsanddiseaseseverityinchildrenandadolescentsbyinfectingvariant
AT leberamyl differencesinsarscov2clinicalmanifestationsanddiseaseseverityinchildrenandadolescentsbyinfectingvariant
AT wanghuanyu differencesinsarscov2clinicalmanifestationsanddiseaseseverityinchildrenandadolescentsbyinfectingvariant
AT mejiasasuncion differencesinsarscov2clinicalmanifestationsanddiseaseseverityinchildrenandadolescentsbyinfectingvariant